Shimla, Dec 29,
A recent drug quality analysis by the Central Drugs Standard Control Organization (CDSCO) uncovered a concerning trend: 27 of 111 substandard drug samples originated from pharmaceutical companies in Himachal Pradesh, a leading hub for medicine manufacturing in India. These drugs, distributed nationwide, raise serious public health concerns.
The affected drugs, manufactured primarily in Baddi, Barotiwala, Nalagarh, and other industrial areas of the state, included common medications like Glimepride, Pioglitazone, and Metformin. Issues ranged from incorrect dosage and inadequate dissolution to labeling errors and improper storage.
Noteworthy that this is not an isolated incident. Recurring quality control issues in Himachal Pradesh’s pharmaceutical sector this year have sparked serious concerns about regulatory oversight.
Also read HP High Court demands response from State Officials on allegations against former Drug Controller
The state’s drug control administration has issued notices to the companies involved, demanding the recall of substandard batches.
